Read Our News And Press Releases

Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

Oct 10 2023

Hartman, CEO and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast

By Admin|2023-10-09T16:58:07-04:00October 10th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, October 10, 2022 – Halberd Corporation (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S. Felder were recently interviewed on “The Street Reports Podcast” to update the public on several of the company’s important projects: The significant results to-date of Halberd’s proprietary nasal spray testing ...

Oct 4 2023

Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)

By Admin|2023-10-03T20:16:16-04:00October 4th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA October 4, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing: 25% reduction in Neuron Specific Enolase ...

Sep 20 2023

Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts

By Admin|2023-09-19T19:50:39-04:00September 20th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA September 20, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd’s proprietary nasal spray for suppressing ...

Sep 6 2023

Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)

By Admin|2023-09-06T05:46:15-04:00September 6th, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Anecdotal Results of Halberd’s Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers Jackson Center, PA September 6, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd’s patent-pending nasal spray to mitigate ...

Aug 22 2023

Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)

By Admin|2023-08-21T18:31:47-04:00August 22nd, 2023|Featured, Investor News, News, Press Releases|0 Comments

Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product Jackson Center, PA August 22, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model ...

May 31 2023

Halberd CEO Mid-Quarter Update

By Admin|2023-05-31T05:53:16-04:00May 31st, 2023|Investor News, News, Press Releases, Uncategorized, Update Letter|0 Comments

Jackson Center, PA May 31, 2023 – Halberd Corporation (OTC-PINK: "HALB”) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts. Mississippi State University (MSU) has completed the impacts and sample collection for ...

May 23 2023

Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete

By Admin|2023-05-22T20:43:29-04:00May 23rd, 2023|Featured, Investor News, Press Releases|0 Comments

MSU is ahead of schedule and continues testing program Jackson Center, PA May 23, 2023 – Halberd Corporation (OTC-PINK: "HALB”) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray. The nasal spray is designed to eliminate ...

May 9 2023

Halberd Pre-Clinical Test Protocol Approved

By Admin|2023-05-08T18:54:10-04:00May 9th, 2023|Investor News, News, Press Releases|0 Comments

Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month End Jackson Center, PA May 9, 2023 – Halberd Corporation (OTC-PINK: "HALB”) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered. Parameter quantification and preliminary data gathering ...

May 2 2023

Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma

By Admin|2023-05-01T20:26:07-04:00May 2nd, 2023|Investor News, Medical, News, Press Releases|0 Comments

Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process Jackson Center, PA May 2, 2023 – Halberd Corporation (OTC-PINK: "HALB”) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of ...

Apr 25 2023

Halberd Corporation 1Q23 CEO Letter

By Admin|2023-04-24T20:53:26-04:00April 25th, 2023|Investor News, News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application ...

Previous 234 Next